Amedisys Inc (NASDAQ:AMED) COO Sells $47,176.50 in Stock

Amedisys Inc (NASDAQ:AMED) COO Christopher Gerard sold 350 shares of Amedisys stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $134.79, for a total value of $47,176.50. Following the completion of the transaction, the chief operating officer now owns 25,381 shares of the company’s stock, valued at approximately $3,421,104.99. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

AMED stock traded up $1.27 during trading on Wednesday, hitting $134.76. The stock had a trading volume of 249,287 shares, compared to its average volume of 398,638. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.88 and a quick ratio of 0.88. Amedisys Inc has a twelve month low of $97.38 and a twelve month high of $141.98. The stock has a market capitalization of $4.18 billion, a P/E ratio of 37.12, a PEG ratio of 1.95 and a beta of 1.46. The company’s 50-day moving average price is $132.82 and its two-hundred day moving average price is $123.53.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 31st. The health services provider reported $1.21 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.24. Amedisys had a return on equity of 27.23% and a net margin of 6.84%. The business had revenue of $492.98 million during the quarter, compared to analysts’ expectations of $489.66 million. During the same quarter in the prior year, the firm earned $1.00 earnings per share. The business’s revenue was up 19.8% compared to the same quarter last year. As a group, sell-side analysts expect that Amedisys Inc will post 4.11 EPS for the current fiscal year.

A number of equities analysts have issued reports on AMED shares. Oppenheimer increased their price target on Amedisys from $140.00 to $150.00 in a research report on Thursday, August 1st. Barclays raised their price objective on Amedisys from $120.00 to $125.00 and gave the company an “equal weight” rating in a report on Monday, August 5th. ValuEngine upgraded Amedisys from a “hold” rating to a “buy” rating in a research report on Thursday, September 5th. BidaskClub raised Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 26th. Finally, Jefferies Financial Group set a $150.00 target price on Amedisys and gave the company a “buy” rating in a research report on Monday, July 8th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Amedisys has a consensus rating of “Buy” and an average price target of $135.90.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Rehmann Capital Advisory Group acquired a new position in Amedisys in the 2nd quarter valued at $31,000. Vestmark Advisory Solutions Inc. purchased a new position in Amedisys in the 2nd quarter valued at $258,000. Harvest Fund Management Co. Ltd boosted its stake in Amedisys by 78.8% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 735 shares of the health services provider’s stock worth $89,000 after purchasing an additional 324 shares during the last quarter. Maverick Capital Ltd. acquired a new stake in Amedisys during the 2nd quarter worth $54,000. Finally, Magnetar Financial LLC purchased a new stake in shares of Amedisys during the second quarter worth $4,553,000. Hedge funds and other institutional investors own 89.28% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Article: What is a Leveraged Buyout (LBO)?

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply